Sizopin100 mg

Sizopin is an atypical (second-generation) antipsychotic reserved for specific, difficult-to-treat clinical situations because of its serious safety profile and the intensive monitoring it requires. Indications below are grouped by strength of evidence.

Established / approved uses

• Treatment-resistant schizophrenia: for severely ill patients with schizophrenia who have not responded adequately to at least two other antipsychotic agents given at adequate doses for an adequate duration.
• Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged, based on history and current clinical state, to be at chronic risk of suicidal behavior.

Off-label / specialist-only uses (not formally approved)

• Psychosis associated with Parkinson's disease that has failed standard measures, occasionally used at low doses under close specialist supervision.
• Treatment-resistant bipolar disorder with prominent psychotic features, as an adjunct under psychiatric specialist care.

Sizopin is not approved for elderly patients with dementia-related psychosis; a boxed warning specifically advises against use in this population because of increased mortality risk.

Each tablet contains Clozapine INN as the active ingredient, commonly available in strengths of 25 mg, 50 mg, 100 mg, and 200 mg. In some markets, an orally disintegrating tablet and an oral suspension formulation of Clozapine are also available. Excipients vary by manufacturer; refer to the product-specific package insert for the complete excipient list.

Sizopin is a dibenzodiazepine-derivative atypical antipsychotic, historically notable as the first agent shown to be effective in schizophrenia that had not responded to other antipsychotics. Unlike many older ("typical") antipsychotics, Sizopin has a relatively low propensity to cause extrapyramidal symptoms, but this benefit is offset by a distinctive and serious adverse-effect profile — most importantly a risk of severe, potentially fatal neutropenia — which restricts its use to patients who genuinely need it and who can be enrolled in a mandatory blood-count monitoring program.

Because of this risk-benefit balance, Sizopin is considered a "last-line" option in schizophrenia, used only after other antipsychotics have failed, and it is dispensed only through controlled distribution programs that link prescribing and dispensing to regular absolute neutrophil count (ANC) results.

Sizopin belongs to the atypical (second-generation) antipsychotic class, specifically the dibenzodiazepine chemical subgroup.

Mechanism of action

The precise mechanism by which Clozapine exerts its antipsychotic effect is not fully established. It is believed to act through antagonism at multiple central receptors, including dopamine receptors (D1, D2, D3, D4, D5), serotonin receptors (5-HT2A, 5-HT2C, 5-HT3, 5-HT6), as well as alpha-adrenergic, histaminergic (H1), and muscarinic cholinergic receptors. Its relatively low affinity for D2 receptors compared with typical antipsychotics is thought to explain its low risk of extrapyramidal symptoms, while its broad receptor-binding profile underlies its distinctive side-effect pattern (sedation, hypotension, hypersalivation, anticholinergic effects).

Pharmacokinetics

Clozapine is well absorbed orally; food does not significantly affect the extent of absorption, so it can be taken with or without meals. It is extensively metabolized in the liver, principally by the CYP1A2 enzyme, with additional contributions from CYP3A4 and CYP2D6. Metabolites are largely inactive and are excreted in urine and feces. Elimination half-life is variable, generally in the range of 8–12 hours at steady state. Smoking induces CYP1A2 and can lower Clozapine levels, so plasma levels may need to be reassessed after a change in smoking status.

Sizopin is taken by mouth, with or without food, as food does not meaningfully affect absorption. Standard tablets should be swallowed; where an orally disintegrating tablet formulation is used, it should be placed on the tongue and allowed to disintegrate, then swallowed with saliva or with the aid of liquid, without chewing. Doses are usually divided (e.g., twice daily), with a larger portion often taken at bedtime because of sedation. Patients should not stop or change the dose of Sizopin without medical advice, and must attend all scheduled blood tests required by the monitoring program.

Sizopin is metabolized mainly by CYP1A2, with contributions from CYP2D6 and CYP3A4, so drugs affecting these enzymes can significantly alter its levels.

Drugs that increase Sizopin levels

• Strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin): can markedly raise Sizopin levels; dose reduction (often to about one-third) is generally required if co-administration cannot be avoided.
• CYP2D6/CYP3A4 inhibitors (e.g., some antidepressants, macrolide antibiotics, azole antifungals): may increase Sizopin levels; monitor closely and reduce dose if needed.

Drugs that decrease Sizopin levels

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): can substantially lower Sizopin levels and reduce efficacy; concomitant use is generally not recommended.
• Tobacco smoking induces CYP1A2 and lowers Sizopin levels; a change in smoking status during treatment can require dose adjustment.

Additive risk interactions

• Other bone-marrow suppressants (e.g., carbamazepine, certain chemotherapy agents): increase the risk of severe neutropenia and should generally be avoided with Sizopin.
• Anticholinergic drugs (e.g., benztropine, diphenhydramine): additive anticholinergic burden, increasing risk of severe constipation, ileus, and urinary retention; avoid where possible.
• CNS depressants (benzodiazepines, opioids, alcohol): additive sedation, respiratory depression, and hypotension; benzodiazepines in particular have been linked to rare cases of severe cardiorespiratory collapse when combined with Sizopin, especially during initial dosing.
• QT-prolonging drugs (e.g., certain antiarrhythmics, some antibiotics, other antipsychotics): additive risk of QT prolongation and arrhythmia.
• Antihypertensives and other hypotension-causing drugs: additive orthostatic hypotension risk (see Precautions and Warnings).

The most commonly reported adverse effects of Sizopin, occurring in a substantial proportion of patients, include:

• Sedation/drowsiness (very common)
• Hypersalivation (drooling, including at night)
• Tachycardia (fast heart rate)
• Constipation
• Dizziness or lightheadedness, orthostatic hypotension
• Weight gain
• Nausea
• Fever (usually transient, in the first weeks)
• Tremor

Serious adverse effects — including severe neutropenia, seizures, myocarditis/cardiomyopathy, severe gastrointestinal hypomotility (constipation progressing to bowel obstruction), neuroleptic malignant syndrome, and marked metabolic changes (hyperglycemia, dyslipidemia) — are covered in detail under Precautions and Warnings, as they require specific monitoring and action rather than being routine side effects.

Pregnancy: Data on the use of Sizopin in pregnancy are limited. Antipsychotics, including Sizopin, used during the third trimester have been associated with extrapyramidal and/or withdrawal symptoms in the newborn, such as agitation, abnormal muscle tone, tremor, drowsiness, or feeding difficulty. Sizopin should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close physician supervision; a pregnancy exposure registry exists in some countries to monitor outcomes. Do not start or stop Sizopin during pregnancy without consulting a physician.

Lactation: Sizopin passes into breast milk. Because of the potential for serious adverse effects in a breastfed infant (including sedation and hematologic effects), a decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue the drug, taking into account the importance of treatment to the mother and monitoring the infant for adverse effects if breastfeeding continues.

Boxed warnings

• Severe neutropenia: Sizopin can cause severe, potentially fatal neutropenia. Baseline absolute neutrophil count (ANC) must be obtained before starting, and regular ANC monitoring is mandatory throughout treatment through an approved monitoring/registry program; treatment must be interrupted or stopped according to defined ANC thresholds.
• Orthostatic hypotension, bradycardia, and syncope: can occur, particularly during initial dose titration, and rarely progress to cardiac arrest; start at a low dose and titrate slowly with divided dosing.
• Seizures: risk is dose-related; use caution in patients with a seizure history and avoid rapid dose increases.
• Myocarditis and cardiomyopathy: rare but can be fatal, most often within the first two months (myocarditis) or after about 8 weeks (cardiomyopathy) of treatment; discontinue immediately if suspected and refer for cardiac evaluation.
• Increased mortality in elderly patients with dementia-related psychosis: Sizopin is not approved for this population.

Other important precautions

• Mandatory monitoring program: Sizopin must never be initiated, continued, or dispensed outside the required blood-count monitoring infrastructure; this is a condition of safe use, not an optional precaution.
• Gastrointestinal hypomotility: potent anticholinergic effects can cause constipation that, in some cases, progresses to bowel obstruction, ileus, or bowel ischemia/perforation, which can be fatal. Screen for constipation before starting and monitor bowel function regularly; treat constipation promptly and avoid other anticholinergic drugs where possible.
• Metabolic effects: significant weight gain, hyperglycemia (including new-onset diabetes and rare diabetic ketoacidosis), and dyslipidemia can occur; monitor weight, blood glucose, and lipids at baseline and periodically.
• QT prolongation: use caution in patients with risk factors for QT prolongation or when combined with other QT-prolonging drugs.
• Neuroleptic malignant syndrome (NMS): a rare but potentially fatal reaction (fever, muscle rigidity, altered mental status, autonomic instability); discontinue immediately if suspected.
• Hepatotoxicity: rare but potentially severe liver injury has been reported; monitor liver function if symptoms suggestive of liver injury occur.
• Sedation and impaired performance: caution with driving or operating machinery until individual response to Sizopin is known.
• Eosinophilia: can occur, occasionally with involvement of the heart or other organs; evaluate if it occurs.

Sizopin must never be used casually, without prescription, or outside the mandatory monitoring framework, given the seriousness of its potential adverse effects.

Overdose with Sizopin can cause drowsiness progressing to sedation and coma, hypersalivation, tachycardia, hypotension, respiratory depression, aspiration pneumonia, and seizures; anticholinergic toxicity (dry mouth, blurred vision, urinary retention, delirium) and cardiac arrhythmias can also occur, and fatalities have been reported, particularly with very large ingestions or when combined with other CNS depressants.

Suspected overdose of Sizopin is a medical emergency. Seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is supportive, with close monitoring of cardiac and respiratory status in a hospital setting; there is no specific antidote. Do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

Use with caution; dose reduction and slower titration may be necessary in significant renal impairment.

Hepatic impairment

Use with caution; dose reduction may be necessary. Sizopin should generally be avoided in patients with severe, active liver disease.

CYP2D6 poor metabolizers

These patients may have higher Sizopin levels; a lower dose may be necessary.

Elderly

Use with caution because of increased sensitivity to sedation, orthostatic hypotension, and anticholinergic effects; Sizopin is not approved for elderly patients with dementia-related psychosis (see Precautions and Warnings for the associated mortality risk).

Smokers

Smoking induces the enzyme that metabolizes Sizopin; starting or stopping smoking during treatment can meaningfully change drug levels and may require dose adjustment.

See Pediatric Uses for use in children and adolescents, and Pregnancy and Lactation for use during pregnancy and breastfeeding.

Duration of treatment with Sizopin is individualized by the treating psychiatrist based on response and tolerability. Because it is used for treatment-resistant illness, therapy is often long-term/maintenance once a response is achieved, with continued mandatory blood-count monitoring throughout treatment. Periodic reassessment of ongoing need is recommended. If discontinuation is required, gradual tapering over 1–2 weeks is preferred over abrupt cessation (see Dosage and Administration).

Clozapine is classified as an atypical (second-generation) antipsychotic, dibenzodiazepine chemical class.

Clozapine acts as an antagonist at multiple central nervous system receptors, most notably dopamine (D1–D5) and serotonin (5-HT2A, 5-HT2C, 5-HT3, 5-HT6) receptors, along with alpha-adrenergic, histamine H1, and muscarinic cholinergic receptors. Its comparatively weak D2-receptor blockade relative to typical antipsychotics is thought to underlie its low rate of extrapyramidal symptoms, while its broad multi-receptor activity is believed to contribute both to its unique efficacy in treatment-resistant schizophrenia and to its characteristic side-effect profile (sedation, hypersalivation, hypotension, anticholinergic effects).

B

The safety and effectiveness of Sizopin have not been established in pediatric patients (below 18 years of age). Sizopin is not recommended for use in children or adolescents outside of specialist clinical trial settings, and should only be considered in this age group under the direct supervision of a child/adolescent psychiatrist experienced in its use, with the same mandatory ANC monitoring that applies to adults.